Search Result

Results for "

HSP70 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (6) Aryl Hydrocarbon Receptor (1) Autophagy (9) Bacterial (5) Bcl-2 Family (2) DNA/RNA Synthesis (1) HDAC (1) Hedgehog (1) Histone Methyltransferase (2) HMG-CoA Reductase (HMGCR) (7) HSP (32) Isotope-Labeled Compounds (1) JNK (1) MDM-2/p53 (1) Monoamine Oxidase (1) NO Synthase (1) Parasite (1) Potassium Channel (7) Sirtuin (3)
By Research Areas:	Cancer (32) Cardiovascular Disease (7) Infection (3) Inflammation/Immunology (1) Metabolic Disease (8) Neurological Disease (6)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10941

VER-155008 Maximum Cited Publications 16 Publications Verification	HSP Autophagy	Neurological Disease Cancer
VER-155008 is an inhibitor of *Hsp70, with IC₅₀s of 0.5 μM, 2.6 μM, and 2.6 μM for Hsp70, Hsc70 and Grp7, respectively, and with a K_d* of 0.3 μM for *Hsp70*.

HY-117282

JG-98 5+ Cited Publications	HSP Apoptosis	Cancer
JG-98, an allosteric heat shock protein 70 (Hsp70) inhibitor, which binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities affecting both cancer cells and tumor-associated macrophages .

HY-122184

PET-16	HSP Apoptosis	Cancer
PET-16 is a selective *HSP70* inhibitor that binds to an allosteric pocket of the substrate-binding domain. PET-16 inhibits the ability of HSP70 to cycle between ATP-bound and ADP-bound states. PET-16 induces apoptosis in multiple myeloma .

HY-18406

HSP70-IN-4	HSP	Cancer
HSP70-IN-4 (Compound YM-01) is an *Hsp70* inhibitor with an IC₅₀ of 3.2 μM. HSP70-IN-4 is not BBB permeable .

HY-149637

HSP70/SIRT2-IN-1	Sirtuin HSP	Cancer
HSP70/SIRT2-IN-1 (Compounds 2a) is a dual inhibitor for SIRT2 and *HSP*70, with IC₅₀ of 17.3±2.0 μM for SIRT2. HSP70/SIRT2-IN-1 has antitumor activity .

HY-149638

HSP70/SIRT2-IN-2	Sirtuin HSP	Cancer
HSP70/SIRT2-IN-2 (Compounds 1a) is a dual inhibitor for SIRT2 and *HSP*70, with IC₅₀ of 45.1±5.0 μM for SIRT2. HSP70/SIRT2-IN-2 has antitumor activity .

HY-12619

DMT003096	HSP	Cancer
DMT003096 is a *HSP70* inhibitor. HSP70 has been reported to be upregulated in various cancers including breast, lung, colon, and cervix .

HY-163854

HSP70-IN-6	HSP Bcl-2 Family Apoptosis	Cancer
HSP70-IN-6 (Compound JL-15) is an inhibitor of *Hsp70-Bim* protein-protein interaction (PPI) (IC₅₀: 70 nM). HSP70-IN-6 induces apoptosis in chronic myeloid leukemia (CML) cells, with EC₅₀s of 0.43 μM(BV173), 0.88 μM (K562), 0.19 μM (K562-R3) .

HY-139144

YM-08	Sirtuin HSP	Neurological Disease Cancer
YM-08 (Compounds 7a) is a brain-penetrant inhibitors of SIRT2,with the IC₅₀ of 19.9 μM. YM-08 also is inhibitor of *Hsp70* .

HY-143400

HSP70-IN-3	HSP Hedgehog	Cancer
HSP70-IN-3 is a potent *HSP70* inhibitor (IC₅₀s of 1.1 and 1.9 μM in ASZ001 and C3H10T1/2, respectively). HSP70-IN-3 has anti-Hh (Hedgehog signaling) activity and anti-proliferative activity and reduces expression of the oncogenic transcription factor GLI1 .

HY-120909

YK5	HSP Apoptosis	Cancer
YK5 is a potent and selective *Hsp70* inhibitor. YK5 selectively and tightly binds to the cytosolic Hsp70s in cancer cells. YK5 has biological activity partly by interfering with the formation of active oncogenic Hsp70/Hsp90/client protein complexes .

HY-10940

Pifithrin-μ 10+ Cited Publications PFTμ; 2-Phenylethynesulfonamide	MDM-2/p53 HSP Autophagy	Neurological Disease Cancer
Pifithrin-μ is an inhibitor of p53 and *HSP70*, with antitumor and neuroprotective activity.

HY-148745

JG-258	HSP	Cancer
JG-258 is an inactive negative control for Hsp70 inhibitors .

HY-12622

HSP70-IN-1 1 Publications Verification	HSP	Cancer
HSP70-IN-1 is a heat shock protein (HSP) inhibitor; inhibits the growth of Kasumi-1 cells with an IC₅₀ of 2.3 μM.

HY-100110

KNK437 2 Publications Verification Heat Shock Protein inhibitor I	HSP	Cancer
KNK437 is a HSP inhibitor, and inhibits the induction of HSP105, HSP70, and HSP40.

HY-124805

MAL3-101	HSP	Cancer
MAL3-101 is a potent *HSP70* allosteric inhibitor. MAL3-101 inhibits HSP70 ATPase activity by blocking Hsp40 co-chaperone interaction. MAL3-101 can be used for researching muscle invasive bladder cancer (MIBC) .

HY-162008

S1g-10	HSP Bcl-2 Family	Cancer
S1g-10 is a *Hsp70/Bim* inhibitor, and shows antitumor activity in chronic myeloid leukemia cells .

HY-116279

JG-48	HSP	Neurological Disease
JG-48 is a *Hsp70* inhibitor that can reduce tau levels in models of tauopathy .

HY-107599

AEG3482	JNK Apoptosis	Neurological Disease
AEG3482 is a potent antiapoptotic compound that inhibits Jun kinase (JNK) activity through induced expression of heat shock protein 70 (HSP70). AEG3482 directly binds HSP90, thereby facilitating HSF1-dependent expression of HSP70 and HSP25 .

HY-116683

116-9e MAL2-11B	HSP DNA/RNA Synthesis	Infection Cancer
116-9e (MAL2-11B) is a Hsp70 co-chaperone DNAJA1 inhibitor. 116-9e inhibits Simian Virus 40 (SV40) replication and DNA synthesis. 116-9e inhibits tumor antigen (TAg)’s endogenous ATPase activity and the TAg-mediated activation of Hsp70 .

HY-15098

Apoptozole 5+ Cited Publications Apoptosis Activator VII	HSP Apoptosis	Cancer
Apoptozole (Apoptosis Activator VII) is an inhibitor of the ATPase domain of Hsc70 and *Hsp70, with K_d*s of 0.21 and 0.14 μM, respectively, and can induce apoptosis.

HY-N0754

Eupalinolide A	HSP	Inflammation/Immunology
Eupalinolide A, isolated from Eupatorium lindleyanum, induces the expression of HSP70 via the activation of HSF1 by inhibiting the interaction between HSF1 and HSP90 .

HY-111002

Displurigen NSC375009	HSP	Others
Displurigen (NSC375009) disrupts human embryonic stem cell pluripotency by targeting HSPA8. Displurigen inhibits ATPase activity of HSP70 (IC₅₀ = 225 μM) .

HY-18619

YL-109 2 Publications Verification	Aryl Hydrocarbon Receptor	Cancer
YL-109 is an antitumor agent that can induce carboxyl terminus of Hsp70-interacting protein (CHIP) expression through aryl hydrocarbon receptor (AhR) signaling. YL-109 has ability to inhibit breast cancer cell growth and invasiveness .

HY-124611

JG-231	HSP	Cancer
JG-231 is an analogue of JG-98 with anticancer effects. JG-231 inhibits the interaction of *Hsp70-BAG3. JG-231 inhibits* MDA-MB-231 heterograft tumor models of triple negative breast cancer (TNBC) .

HY-168566

EV206	HSP	Cancer
EV206 is a potent *Hsp70* inhibitor. EV206 shows antiproliferative activity. EV206 induces apoptosis and increases the protein expression of cleaved PARP and caspase-3. EV206 shows antitumor activity .

HY-114664

KNK423	HSP	Infection Cancer
KNK423 is a specific heat shock protein (HSP) synthesis inhibitor. KNK423 improves the efficiency of Amphotericin B in inhibiting resistant Aspergillus terreus by blocking *HSP70*. KNK423 can be used in cancer and bacterial infection research .

HY-115467

MitoBloCK-10 2 Publications Verification	HSP	Metabolic Disease
MitoBloCK-10 (MB-10) is the first small molecule modulator to attenuate protein-associated motor (PAM) complex activity. MitoBloCK-10 (MB-10) inhibits Tim44 (C-terminal domain) binding to the precursor and to Hsp70 .

HY-18399

YM-1	HSP NO Synthase	Cancer
YM-1 is a stable and soluble MKT-077 (HY-15096) analog and an orally active *Hsp70* inhibitor. YM-1 induces cell death of HeLa cells and up-regulates the level of p53 and p21 proteins .

HY-126601

Malonganenone A	Parasite HSP	Infection
Malonganenone A is an antimalarial marine alkaloid that disrupts the interaction between PfHsp70-x and Hsp40. Malonganenone A inhibits plasmodial and not human Hsp70 ATPase activity (Hsp40-stimulated), and hindered the aggregation suppression activity of PfHsp70-x .

HY-17504B

Rosuvastatin Sodium 10+ Cited Publications ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504

Rosuvastatin Calcium 10+ Cited Publications Rosuvastatin hemicalcium; ZD 4522 Calcium	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-101508

GNA002	Histone Methyltransferase	Cancer
GNA002 is a highly potent, specific and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC₅₀ of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes .

HY-162567

AP-4-139B	HSP	Cancer
AP-4-139B is a heat shock protein 70 inhibitor (IC₅₀=180 nM). *HSP70* is a protein that is overexpressed in many types of cancer and is closely related to the survival and proliferation of tumor cells. AP-4-139B exhibits significant cytotoxicity to tumor cells, particularly in colorectal cancer cells. AP-4-139B can be used for cancer research .

HY-114211

SGC8158	Histone Methyltransferase HSP	Cancer
SGC8158 is an inhibitor of PRMT7 and can be used to study the cellular function of PRMT7. SGC8158 decreases monomethylarginine levels of Hsp70 (the best characterized PRMT7 substrate). SGC8158 induces growth inhibition in various cancer cells (IC₅₀: 2-9 μM), as well as multidrug-resistant (MDR) cancer cells. SGC8158 also enhances Doxorubicin (HY-15142A) induced DNA damage and Its cytotoxicity .

HY-17504R

Rosuvastatin Calcium (Standard) 5+ Cited Publications Rosuvastatin hemicalcium (Standard); ZD 4522 Calcium (Standard)	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (Calcium) (Standard) is the analytical standard of Rosuvastatin (Calcium). This product is intended for research and analytical applications. Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504A

Rosuvastatin ZD 4522	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504BS2

Rosuvastatin-13C,d3 sodium ZD 4522-₁₃C,d₃ sodium; X-Plended-₁₃C,d₃ sodium; Crestor-₁₃C,d₃ sodium	Autophagy Bacterial HMG-CoA Reductase (HMGCR) Potassium Channel Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease
Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504D

(3S,5R)-Rosuvastatin	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy	Cardiovascular Disease Metabolic Disease
(3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504C

(3R,5R)-Rosuvastatin	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy	Cardiovascular Disease Metabolic Disease
(3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-13644

Gusperimus 15-Deoxyspergualin	Others	Others
Gusperimus is a fully synthetic racemate that has a novel mechanism of action by binding to the intracellular heat shock protein hsp70 and interfering with intracellular signal transduction. This mechanism of action can enhance the effect of immunosuppressive therapy. Gusperimus can inhibit the differentiation of T cells into cytotoxic T cells, reduce the expression of IL-2 receptors on CD4 and CD8 cells, and inhibit IFN-γ-induced B cell maturation. In addition, when used with cyclosporine, tacrolimus or mycophenolate mofetil, Gusperimus can enhance the immunosuppressive effect and prevent allogeneic transplant rejection.

HY-155580

MAO A/HSP90-IN-2	Monoamine Oxidase HSP	Cancer
MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC₅₀ values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases *HSP70* expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape ^[1].

HY-118783

2-Hexyl-4-pentynoic acid (±)-2-Hexyl-4-pentynoic acid	HDAC HSP	Neurological Disease
2-Hexyl-4-pentynoic acid ((±)-2-Hexyl-4-pentynoic acid), valproic acid (VPA) derivative, exhibits potential roles of HDAC inhibition (IC₅₀=13 μM) and HSP70 induction. Potent neuroprotective effects. 2-Hexyl-4-pentynoic acid causes histone hyperacetylation and protect against glutamate-induced excitotoxicity in cultured neurons . 2-Hexyl-4-pentynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0754

Eupalinolide A	Classification of Application Fields Melilotus albus Desr. Terpenoids Sesquiterpenes Source classification Plants Compositae Disease Research Fields Inflammation/Immunology	HSP
Eupalinolide A, isolated from Eupatorium lindleyanum, induces the expression of HSP70 via the activation of HSF1 by inhibiting the interaction between HSF1 and HSP90 .

HY-126601

Malonganenone A	Infection Structural Classification Alkaloids Classification of Application Fields Animals Other Alkaloids Source classification Disease Research Fields	Parasite HSP
Malonganenone A is an antimalarial marine alkaloid that disrupts the interaction between PfHsp70-x and Hsp40. Malonganenone A inhibits plasmodial and not human Hsp70 ATPase activity (Hsp40-stimulated), and hindered the aggregation suppression activity of PfHsp70-x .

Cat. No.	Product Name	Chemical Structure

HY-17504BS2

Rosuvastatin-13C,d3 sodium

Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

Cat. No.	Product Name		Classification

HY-118783

2-Hexyl-4-pentynoic acid (±)-2-Hexyl-4-pentynoic acid		Alkynes
2-Hexyl-4-pentynoic acid ((±)-2-Hexyl-4-pentynoic acid), valproic acid (VPA) derivative, exhibits potential roles of HDAC inhibition (IC₅₀=13 μM) and HSP70 induction. Potent neuroprotective effects. 2-Hexyl-4-pentynoic acid causes histone hyperacetylation and protect against glutamate-induced excitotoxicity in cultured neurons . 2-Hexyl-4-pentynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks